Avistone Biotechnology
Avistone Biotechnology is a China-based biotechnology company running 5 late-stage cancer trials of PLB1004, Vebreltinib and ANS02 in non-small-cell lung cancer.
Overview
Avistone Biotechnology, based in Beijing, China, is a biotechnology company. A commercialisation-stage innovative biopharmaceutical company (Chinese name Anvistone, formerly Beijing Puyuan Anvistone) focused on developing precision cancer medicines, with a manufacturing partner in Ningbo. On ClinicalTrials.gov it is the lead sponsor of 5 recruiting or active phase 2 and phase 3 interventional cancer trials, testing PLB1004, Vebreltinib and ANS02 in non-small-cell lung cancer. The largest, NCT07538804 (A Study to Investigate ANS02 in Participants With EGFR Mutation-Positive Non-Small Cell Lung Cancer), plans to enrol 294 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry, checked on 2026-09-11; company facts are from the official website.
Similar pages
not linked directly; found by shared links- CompanyMaia Biotechnology
Shares Non-small-cell lung cancer and the tag ctgov-sponsor.
- CompanySTCube
Shares Non-small-cell lung cancer and the tag ctgov-sponsor.
- CompanyCivaTech Oncology
Shares Non-small-cell lung cancer and the tag ctgov-sponsor.
- CompanyKrystal Biotech
Shares Non-small-cell lung cancer and the tag ctgov-sponsor.
- CompanymAbxience Research S.L.
Shares Non-small-cell lung cancer and the tag ctgov-sponsor.
- CompanyCelltrion
Shares Non-small-cell lung cancer and the tag ctgov-sponsor.
- CompanyCatalYm
Shares Non-small-cell lung cancer and the tag ctgov-sponsor.
- CompanyGenprex
Shares Non-small-cell lung cancer and the tag ctgov-sponsor.